Overview
What is Odylia Therapeutics Inc?
Odylia Therapeutics Inc, located in Atlanta, Georgia, is a unique nonprofit organization dedicated to advancing drug development for rare diseases. With a mission to accelerate the transition of gene therapies from the lab to the clinic, they utilize a non-profit business model that involves collaborating directly with individuals affected by rare diseases. Their primary focus is on three programs: RPGRIP1 and USH1C gene therapies, as well as Brydge Solutions. With a small workforce of five individuals, Odylia Therapeutics Inc is making significant strides in revolutionizing the way treatments for rare diseases are developed and brought to the clinic.
Official website here: www.odylia.org
Is Odylia Therapeutics Inc legitimate?
Odylia Therapeutics Inc is a legitimate nonprofit organization registered as a 501(c)(3) entity. Odylia Therapeutics Inc submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Here are some key statistics you may want to consider:
Executive Compensation: $210,664
Professional Fundraising Fees: $0
Other Salaries and Wages: $391,700
For more financial information, click here
Official website here: www.odylia.org
What is the mission statement of Odylia Therapeutics Inc?
Odylia Therapeutics Inc employs an unusual, non-profit business strategy to expedite the creation of gene therapies for individuals with rare diseases, revolutionizing the process of bringing treatments from the lab to the clinic. Their mission is to speed up the development of these therapies, ultimately altering the trajectory of how treatments are introduced for such diseases. The company's focus is primarily on three key programs: their RPGRIP1 and USH1C gene therapy programs, as well as Brydge Solutions.
Official website here: www.odylia.org
Who is the CEO of Odylia Therapeutics Inc?
Ashley Winslow is the Ceo Cso of Odylia Therapeutics Inc. The CEO's salary of Odylia Therapeutics Inc is $210,664 and their total compensation is $210,664.
Official website here: www.odylia.org
What is the revenue of Odylia Therapeutics Inc?
Who are the executives of Odylia Therapeutics Inc and what are their salaries?
The average compensation at Odylia Therapeutics Inc during 2022 was $120,473. There are 5 employees and 6 volunteers at Odylia Therapeutics Inc.
Here are 6 key members and their salaries (Odylia Therapeutics Inc's CEO's salary is $210,664 and their total compensation is $210,664):
- Ashley Winslow (Ceo Cso)
- Scott Dorfman (Board Member) [Trustee/Director]
- Brian Fenton (Board Member) [Trustee/Director]
- Mat Pletcher (Board Member) [Trustee/Director]
- Luk Vanderbergh (Board Member) [Trustee/Director]
- Susie Trotochaud (Secretary)
Official website here: www.odylia.org
Where can I find the form 990 for Odylia Therapeutics Inc?
The Odylia Therapeutics Inc’s most recent form 990 was submitted in 2022 and can be accessed here
Official website here: www.odylia.org
Learn more at the official website: www.odylia.org
Mission Statement of Odylia Therapeutics Inc
Odylia Therapeutics Inc, with its unique non-profit business model, is dedicated to expediting the development of gene therapies for individuals affected by rare diseases. This innovative approach aims to revolutionize the way treatments transition from laboratory to clinical settings. The organization's primary mission is to accelerate the process of bringing life-changing therapies to those who need them most, thereby altering the conventional path of treatment development.
Odylia Therapeutics Inc's mission is accomplished through its commitment to three key programs. The first is centered around the RPGRIP1 and USH1C gene therapy programs, which focus on treating individuals with specific rare diseases. The second program, Brydge Solutions, provides support and resources to help facilitate the successful transition of these therapies from the lab to the clinic. By utilizing a non-profit business model, Odylia Therapeutics Inc is able to prioritize the needs of patients and make a significant impact on the lives of those suffering from rare diseases.
Impact
This information is meant to be a general summary of Odylia Therapeutics Inc. Please take the time to review official sources before making any decisions based upon the content provided here.
Saturday, July 20, 2024
Odylia Therapeutics Inc is making a significant impact by accelerating the development of gene therapies for people with rare diseases. They are actively advancing drug development in this area, with a focus on programs like RPGRIP1 and USH1C gene therapy, along with Brydge Solutions. By utilizing a unique, non-profit business model, Odylia is changing the way treatments are brought from the lab to the clinic. Their work in medical research is paving the way for innovative solutions in the field of gene therapy, offering hope and potential cures for individuals affected by rare diseases.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Assets and Liabilities:
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
BUSINESS REVENUE:SERVICE/FEE
Revenue
$76,500
BUSINESS REVENUE:LICENSING IN
Revenue
$30,861
Organization Details
Founding Year
2017
Phone
(770) 842-9741
Principal Officer
Ashley Winslow
Main Address
1447 PEACHTREE ST NE, ATLANTA, GA, 30309
Website
www.odylia.org
NTEE Category
Code: H41 - Medical research
If you are a representative of Odylia Therapeutics Inc and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.